Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Gilde Healthcare

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 90
Average round size
The average size of a deal this fund participated in
Portfolio companies 60
Rounds per year 2.25
Lead investments 26
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 30
Key employees 18
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Pharmaceutical

Gilde Healthcare appeared to be the VC, which was created in 1982. The main office of represented VC is situated in the Utrecht. The fund was located in Europe if to be more exact in The Netherlands.

The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Hospital. Among the most popular portfolio startups of the fund, we may highlight CVRx, Evotec, Agendia.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gilde Healthcare, startups are often financed by Morgenthaler Ventures, Ysios Capital, QuestMark Partners. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Morgenthaler Ventures, Gimv. In the next rounds fund is usually obtained by Morgenthaler Ventures, Gimv, Novo Holdings.

The overall number of key employees were 14.

Comparing to the other companies, this Gilde Healthcare performs on 9 percentage points more the average number of lead investments. When the investment is from Gilde Healthcare the average startup value is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The top activity for fund was in 2012. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Gilde Healthcare:
Typical Co-investors
Gilde Healthcare is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Gilde Healthcare:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angel Tech Investors (ATI) -
Apex Black -
C-Bridge Capital China, Shanghai
Cadence Growth Capital Bayern, Germany, Grünwald
Citadele Banka AS Latvia, Riga, Vidzeme
Community Development Financial Institutions Fund (CDFI Fund) -
GeoEye Dulles, United States, Virginia
Groupe Galeries Lafayette France, Ile-de-France, Paris
Hydra Startup Studio Montevideo, Uruguay
Jonathan Kalman Haverford, Pennsylvania, United States
KB Partners Highland Park, Illinois, United States
Nanjing Guanghe Hudong Touzi China, Jiangsu, Nanjing
New York Ventures New York, New York, United States
Probing VC China, Shanghai
Saudi Venture Capital Company Ar Riyad, Riyadh, Saudi Arabia
Sony Semiconductor Japan, Kanagawa Prefecture, Yokohama
Spark Centre -
Xiaomi Ventures Beijing, Beijing, China
Yuxi Pacific Pennsylvania, Philadelphia, United States
Ze Way Invest France, Ile-de-France, Paris

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nalu Medical

Health Care
Medical Device
$104M17 Feb 2022 Carlsbad, California, United States

Splice Bio

Life Science
$59M15 Feb 2022 Barcelona, Catalonia, Spain

Big Health

Health Care
$75M19 Jan 2022 San Francisco, California, United States

ProVerum Medical

Health Care
Medical Device
$35M11 Jan 2022 Dublin, County Dublin, Ireland

Spire Health

Health Care
$38M15 Jul 2021 San Francisco, California, United States


$60M29 Apr 2021 Copenhagen, Capital Region of Denmark, Denmark


Life Science
Medical Device
$91M16 Apr 2021 Amsterdam, North Holland, Netherlands

Amphista Therapeutics

$53M17 Mar 2021 Scotland

Volta Medical

Artificial Intelligence
Health Care
Medical Device
$28M05 Jan 2021 Provence-Alpes-Côte d'Azur
Lumicks Raises $93M in Series D Financing

– Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
– The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
– The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.

Amphista Therapeutics Raises $53M in Series B Funding

– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Gilde Healthcare?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: